AK Medical Holdings (HKG:1789) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Jumps 20% This Past Week
AK Medical Holdings (HKG:1789) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Jumps 20% This Past Week
AK Medical Holdings Limited (HKG:1789) shareholders should be happy to see the share price up 20% in the last month. But that cannot eclipse the less-than-impressive returns over the last three years. After all, the share price is down 49% in the last three years, significantly under-performing the market.
愛康醫療控股有限公司(HKG:1789)的股東應該很高興看到股價在上個月上漲了20%。 但這並不能掩蓋過去三年收益不佳的事實。畢竟,股價在過去三年下跌了49%,明顯表現不佳。
Although the past week has been more reassuring for shareholders, they're still in the red over the last three years, so let's see if the underlying business has been responsible for the decline.
儘管過去一週對股東來說更令人放心,但在過去的三年中,他們仍然處於虧損狀態,因此讓我們看看基本業務是否對下降負責。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
雖然一些人仍然相信有效市場假說,但已經證明市場是過度反應的動態系統,投資者並不總是理性的。一個不完美但簡單的方法來考慮公司市場看法的變化是比較每股收益(EPS)的變化和股價的波動。
AK Medical Holdings saw its EPS decline at a compound rate of 11% per year, over the last three years. This reduction in EPS is slower than the 20% annual reduction in the share price. So it seems the market was too confident about the business, in the past.
愛康醫療控股在過去三年以每年11%的複合率下降了EPS。 EPS的減少速度低於股價每年下降20%的速度。因此,市場似乎過去對該業務過於自信。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下圖顯示了EPS隨時間的變化情況(如果您單擊該圖像,則可以查看更多詳細信息)。
We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..
我們很高興地報告,該公司CEO的薪酬比同等資本化公司的大多數CEO都要適度。關注CEO的薪酬很重要,但更重要的問題是公司能否在未來年份中增長收益。在買入或賣出股票之前,我們始終建議仔細審查歷史增長趨勢,此處提供歷史增長趨勢。
A Different Perspective
不同的觀點
While the broader market gained around 22% in the last year, AK Medical Holdings shareholders lost 13% (even including dividends). However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 5% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. Before forming an opinion on AK Medical Holdings you might want to consider these 3 valuation metrics.
儘管整體市場在過去一年中上漲了約22%,但愛康醫療控股股東損失了13%(即使包括分紅派息)。然而,請記住,即使最好的股票有時也會在十二個月的時間內表現不佳。不幸的是,去年的表現可能表明存在未解決的挑戰,因爲表現比過去半個世紀的年化損失5%還要糟糕。我們意識到巴倫·羅斯柴爾德曾說過投資者應該在"街上流血時買進",但我們提醒投資者首先要確信他們在購買高質量的業務。在對愛康醫療控股形成觀點之前,您可能需要考慮這3個估值指標。
But note: AK Medical Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:愛康醫療控股可能不是最佳的股票選擇。因此,請查看這份免費的有過去收益增長(和進一步增長預測)的有趣公司名單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.
請注意,本文引用的市場回報反映了當前在香港證券交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。